½ÃÀ庸°í¼­
»óǰÄÚµå
1462853

¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : Á¦Ç° À¯Çüº°, ±â¼úº°, Áúȯ À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(2023-2030³â)

Global Oxidative Stress Assay Market Size study & Forecast, by Product by Test Type by Technology, by Disease Type, by End-user and Regional Analysis, 2023-2030.

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀåÀº 2022³â¿¡ ¾à 11¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2023-2030³â¿¡´Â 9.45% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

»êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ´Â ¼¼Æ÷ ¹× Á¶Á÷³» Ȱ¼º»ê¼Ò(ROS) ¼öÁذú Ç×»êÈ­Á¦ÀÇ È°¼º»ê¼Ò ÁßÈ­ ´É·ÂÀ» ÃøÁ¤ÇÏ´Â µ¥ »ç¿ëµÇ´Â ¹æ¹ýÀÔ´Ï´Ù. »êÈ­ ½ºÆ®·¹½º´Â Ȱ¼º»ê¼ÒÀÇ »ý¼º·®°ú Ç×»êÈ­Á¦°¡ Ȱ¼º»ê¼ÒÀÇ À¯ÇØÇÑ ¿µÇâÀ» »ó¼âÇÒ ¼ö ÀÖ´Â ½ÅüÀÇ ´É·Â »çÀÌ¿¡ ºÒ±ÕÇüÀÌ ÀÖÀ» ¶§ ¹ß»ýÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ºÒ±ÕÇüÀº ´Ü¹éÁú, ÁöÁú, DNA ¼Õ»óÀ¸·Î À̾îÁö¸ç ¾Ï, ½ÉÇ÷°ü Áúȯ, ½Å°æ ÅðÇ༺ Áúȯ µî ´Ù¾çÇÑ Áúº´°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù.

»êÈ­ ½ºÆ®·¹½º °ü·Ã ÁúȯÀÇ ºóµµ Áõ°¡, Á¦¾àȸ»ç ¹× Çмú±â°üÀÇ ¿¬±¸°³¹ß ³ë·Â Áõ°¡, »êÈ­ ½ºÆ®·¹½º ºÐ¼® ±â¼ú °³¹ßÀº ¸ðµÎ ÇâÈÄ ¼ö³â°£ »êÈ­ ½ºÆ®·¹½º ºÐ¼® ½ÃÀåÀÇ »ó´çÇÑ ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¼¼°è Áúº´ ºÎ´ãÀ» ÁÙÀ̱â À§ÇÑ ÁÖ¿ä ±â¾÷ ¹× Á¤ºÎ ±â°üÀÇ Àû±ØÀûÀÎ ³ë·ÂÀº ¿¬±¸¸¦ ÃËÁøÇϰí Àü ¼¼°è¿¡¼­ »êÈ­ ½ºÆ®·¹½º ºÐ¼®¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Institute for Health Metrics and EvaluationÀÌ 2023³â 4¿ù¿¡ ¹ßÇ¥ÇÑ ¿¬±¸¿¡ µû¸£¸é ´ç´¢º´, ¾Ï, È£Èí±â Áúȯ, ½ÉÇ÷°ü Áúȯ, õ½Ä, COPD µî ¸¸¼º È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ½ÃÀåÀº ´õ¿í È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÈ´Ù, COPD µîÀ» Æ÷ÇÔÇÑ ¸¸¼º È£Èí±â ÁúȯÀº Àü ¼¼°è¿¡¼­ ¾à 4¾ï 5,460¸¸ °Ç¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¶ÇÇÑ ¾Ï, ´ç´¢º´, COPD, ¸¸¼º½ÅÀåÁúȯ, ½ÉÇ÷°üÁúȯ µî ¸¸¼ºÁúȯÀ» ¾Î°í ÀÖ´Â ¹Ì±¹ÀÎ 10¸í Áß 6¸íÀº »êÈ­½ºÆ®·¹½º°¡ ±× ¿øÀÎÀ¸·Î Áö¸ñµÇ°í ÀÖ½À´Ï´Ù. ƯÁ¤ ¸¸¼ºÁúȯÀÇ ¹ßº´ À§Çè Áõ°¡·Î ÀÎÇØ »êÈ­ ½ºÆ®·¹½º °Ë»çÀÇ Çʿ伺Àº Àü ¼¼°è¿¡¼­ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »êÈ­ ½ºÆ®·¹½º°¡ ¸¹Àº ¸¸¼ºÁúȯ°ú ¿¬°üµÇ¾î ÀÖÀ¸¹Ç·Î Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÌ ´Ù¾çÇÑ »ý¸íÀ» À§ÇùÇÏ´Â Áúº´¿¡ ´ëÇÑ »õ·Î¿î Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇØ R&D ºñ¿ëÀ» ´Ã¸®´Â °Í°ú ÇÔ²² »êÈ­ ½ºÆ®·¹½º °Ë»ç¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÈ´Ù°í 2023³â 6¿ù¿¡ ¹ßÇ¥µÈ Pharma R&D Annual Review¿¡ µû¸£¸é Àü ¼¼°è¿¡¼­ ¿¬±¸ ´Ü°è¿¡ ÀÖ´Â ÀǾàǰÀº ¾à 21,292°³ ǰ¸ñ, ¿¬±¸°³¹ß¿¡ Á¾»çÇÏ´Â Á¦¾à±â¾÷Àº 5,529°³»çÀÔ´Ï´Ù. Àüü ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎÀÇ ¾à 17.5%°¡ Áß¼ÒÇü Á¦¾à ¹× ¿¬±¸ ±â¾÷¿¡¼­ »ý»êµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ EFPIAÀÇ 2023³â º¸°í¼­¿¡ µû¸£¸é À¯·´ Á¦¾à¾÷°è´Â 2021³â¿¡ ¾à 480¾ï ´Þ·¯¸¦ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ƯÁ¤ Áúº´¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ Ä¡·áÁ¦¸¦ °³¹ßÇϱâ À§ÇÑ R&D ºñ¿ë Áõ°¡´Â »êÈ­ ½ºÆ®·¹½º¿¡ ´ëÇÑ »ó¾÷Àû ¼ö¿ë¼ºÀ» ³ôÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª 2023-2030³âÀÇ ¿¹Ãø ±â°£ Áß ³ôÀº Àåºñ ºñ¿ëÀº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«À̸ç, 2022³â¿¡´Â ºÏ¹Ì°¡ ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ Ä¡·á¹ý °³¹ß, ÀÇ·á ÀÎÇÁ¶ó °³¼±, ¿©·¯ Á¦¾à ¹× ¹ÙÀÌ¿À Á¦¾à ȸ»ç ¹× ¿¬±¸¼¾ÅÍÀÇ Á¸Àç°¡ ÀÌ Áö¿ª ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¸·´ëÇÑ R&D ºñ¿ë°ú ÇコÄÉ¾î »ê¾÷¿¡¼­ R&D »ç¾÷À» Àå·ÁÇÏ´Â Á¤ºÎ Áö¿øÃ¥À¸·Î ÀÎÇØ ¹Ì±¹ ½ÃÀåÀº 2023³â °¡Àå ³ôÀº Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, 2020³â ¹Ì±¹Àº ÀÇ·á ¹× °Ç°­ R&D¿¡ 2,450¾ï ´Þ·¯ ÀÌ»óÀ» ÁöÃâÇßÀ¸¸ç, ÀÌ ±Ý¾×Àº °è¼Ó Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº Áß±¹°ú Àεµ¿Í °°Àº ½ÅÈï ±¹°¡ÀÌ 2022³â¿¡ ¸¹Àº ¸ÅÃâÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹»óµÊ¿¡ µû¶ó °¡Àå ºü¸¥ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¿¹Ãø ±â°£ Áß ÇコÄɾî ÁöÃâÀÌ Àü¹ÝÀûÀ¸·Î Áõ°¡Çϰí Á¦¾àȸ»ç ¹× Á¤ºÎ Áö¿ø ¿¬±¸±â°üÀÇ ¿¬±¸ºñ ÁöÃâÀÌ ±ÞÁõÇϸ鼭 ÀÌ Áö¿ª ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» Á¶»çÀÇ ¸ñÀûÀº ÃÖ±ÙÀÇ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð¸¦ Á¤ÀÇÇϰí, ÇâÈÄ ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. Á¶»ç ´ë»ó±¹³» »ê¾÷ÀÇ ÁúÀû¡¤¾çÀû Ãø¸é ¾çÃøÀ» Æ÷ÇÔ½Ã۵µ·Ï ¼³°èµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ÇâÈÄ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀÎ ¹× °úÁ¦ µîÀÇ Áß¿äÇÑ Ãø¸é¿¡ °üÇÑ »ó¼¼ Á¤º¸µµ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ ¹× Á¦Ç° Á¦°øÀÇ »ó¼¼ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇϱâ À§ÇÑ ¹Ì½ÃÀû ½ÃÀåÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
    • »ê¾÷ÀÇ ÁøÈ­
    • Á¶»ç ¹üÀ§
  • Á¶»ç ´ë»ó³â
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå ¿ªÇÐ

  • »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀåÀÇ ¿µÇ⠺м®(2020-2030³â)
    • ½ÃÀå ÃËÁø¿äÀÎ
      • Ç¥Àû ÁúȯÀÇ ¸®½ºÅ© Áõ°¡
      • Á¦¾à°ú ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö »ê¾÷ÀÇ ±Þ¼ºÀå
      • Á¤ºÎÀÇ Àû±ØÀûÀÎ ±¸»ó
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
      • ±â±âÀÇ °íºñ¿ë
    • ½ÃÀå ±âȸ
      • Á¦¾àȸ»ç ¹× ¿¬±¸±â°ü¿¡ ÀÇÇÑ ¿¬±¸°³¹ß Ȱµ¿ÀÇ Áõ°¡
      • »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌÀÇ ±â¼ú Áøº¸

Á¦4Àå ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's Five Forces ¿µÇ⠺м®
  • PEST ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • COVID-19 ¿µÇ⠺м®
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð¡¤Á¦¾È

Á¦5Àå ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : Á¦Ç°º°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : Á¦Ç°º°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : Á¦Ç°º° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ±â±¸
    • ¼Ò¸ðǰ
    • ¼­ºñ½º

Á¦6Àå ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : °Ë»ç À¯Çüº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : °Ë»ç À¯Çüº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : °Ë»ç À¯Çüº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • °£Á¢ ¾î¼¼ÀÌ
    • Ç×»êÈ­´É ¾î¼¼ÀÌ
    • È¿¼Ò ±â¹Ý ¾î¼¼ÀÌ
    • Ȱ¼º »ê¼ÒÁ¾ ±â¹Ý ¾î¼¼ÀÌ

Á¦7Àå ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : ±â¼úº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : ±â¼úº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : ±â¼úº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • È¿¼Ò°áÇո鿪ÈíÂøÃøÁ¤¹ý(ELISA)
    • À¯¼¼Æ÷ºÐ¼®
    • Å©·Î¸¶Åä±×·¡ÇÇ
    • Çö¹Ì°æ¹ý
    • ±âŸ

Á¦8Àå ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : Áúȯ À¯Çüº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : Áúȯ À¯Çüº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : Áúȯ À¯Çüº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ½ÉÇ÷°üÁúȯ
    • È£Èí±âÁúȯ
    • ¾Ï
    • ´ç´¢º´
    • ±âŸ

Á¦9Àå ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö »ê¾÷
    • Çмú¿¬±¸±â°ü
    • ÀÓ»ó½ÃÇè¼öʱâ°ü(CRO)
    • ÀÓ»ó ¿¬±¸¼Ò
    • ±âŸ

Á¦10Àå ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå, Áö¿ª ºÐ¼®

  • ÁÖ¿ä ±¹°¡
  • ÁÖ¿ä ½ÅÈï ±¹°¡
  • »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå, Áö¿ªº° ½ÃÀå ½º³À¼ô
  • ºÏ¹Ì
    • ¹Ì±¹
      • Á¦Ç° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • °Ë»ç À¯Çü ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ±â¼úÀÇ ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • Áúȯ À¯Çü ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ÃÖÁ¾»ç¿ëÀÚÀÇ ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
    • ij³ª´Ù
  • À¯·´ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå ½º³À¼ô
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå ½º³À¼ô
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå ½º³À¼ô
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Abcam Limited
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫 Á¤º¸(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì¸¸)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù µ¿Çâ
    • AMS Biotechnology(AMSBIO) AMSBIO
    • Cell Biolabs, Inc.
    • Enzo Life Sciences, Inc.
    • Merck KGaA
    • ImmunoChemistry Technologies
    • Promega Corporation
    • QIAGEN N.V.
    • Thermo Fisher Scientific Inc.
    • Oxford Biomedical Research

Á¦12Àå Á¶»ç ÇÁ·Î¼¼½º

  • Á¶»ç ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
  • Á¶»ç ÀüÁ¦Á¶°Ç
KSA 24.05.03

Global Oxidative Stress Assay Market is valued approximately at USD 1.12 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 9.45% over the forecast period 2023-2030. Oxidative stress assay is a method used to measure the levels of reactive oxygen species (ROS) or the ability of antioxidants to neutralize ROS in cells or tissues. Oxidative stress occurs when there is an imbalance between the production of ROS and the ability of the body to counteract their harmful effects through antioxidants. This imbalance can lead to damage to proteins, lipids, and DNA, and is associated with various diseases including cancer, cardiovascular diseases, and neurodegenerative disorders.

The rising frequency of oxidative stress-related illnesses, the rise in pharmaceutical companies' and academic institutions' R&D endeavoursendeavors, and the development of oxidative stress assays through technology are all expected to contribute to the market's expected significant growth in the upcoming years. Furthermore, positive efforts by major players and governmental organisations to lower the global disease burden are expected to stimulate research, raising the need for oxidative stress assays worldwide. It is anticipated that the market will expand more due to the rising prevalence of oxidative stress-related diseases such diabetes, cancer, respiratory disorders, and cardiovascular disorders. A study released in April 2023 by the Institute for Health Metrics and Evaluation estimates that there are around 454.6 million instances of chronic respiratory disorders worldwide, including asthma, pneumoconiosis, COPD, and others. Furthermore, six out of ten Americans who suffer from a chronic illness-such as cancer, diabetes, COPD, chronic renal disease, cardiovascular disease, and others-also have oxidative stress as a contributing factor. The need for oxidative stress tests is predicted to rise globally due to an increased risk of developing certain chronic health disorders. Given that oxidative stress is linked to a number of chronic diseases, it is anticipated that the need for oxidative stress tests would rise in tandem with pharmaceutical and biotechnology companies' increasing R&D spending to create novel treatments for various life-threatening disorders. The Pharma R&D Annual Review, which was released in June 2023, states that there were around 21,292 pharmaceutical drugs in research phases worldwide and 5,529 pharmaceutical businesses engaged in R&D. About 17.5% of all pharmaceutical pipeline medications are produced by small-to-midsized pharmaceutical and research enterprises. Furthermore, the European pharmaceutical industry spent around USD 48 billion on research and development efforts in 2021, according to the EFPIA 2023 report. It is anticipated that rising R&D costs to create innovative therapeutic medications for specific illnesses will boost oxidative stress's commercial acceptance. However, the hHigh cCost of iInstruments stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Oxidative Stress Assay Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. In 2022, North America accounted dominated the market withfor the largest share of the global market for oxidative stress assays. The development of innovative treatments for various diseases and improved healthcare infrastructure, along with the presence of several pharmaceutical and biopharmaceutical businesses and research centers, are driving the expansion of the regional market. Due to significant R&D expenditures and supportive government measures to encourage R&D operations in the healthcare industry, the U.S. market held the highest share in 2023. In 2020, the United States spent over USD 245 billion on medical and health research and development, and this amount is projected to rise in the years to come. Asia Pacific is anticipated to grow at the fastest CAGR since rising nations like China and India are predicted to produce significant amounts of revenue in 2022. Furthermore, throughout the course of the forecast period, rising healthcare spending generally and a sharp increase in R&D spending by pharmaceutical companies and government-funded research institutes are expected to propel regional market expansion.

Major market player included in this report are:

  • Abcam Limited
  • AMS Biotechnology (AMSBIO)AMSBIO
  • Cell Biolabs, Inc.
  • Enzo Life Sciences, Inc.
  • Merck KGaA
  • ImmunoChemistry Technologies
  • Promega Corporation
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
  • Oxford Biomedical Research

Recent Developments in the Market:

  • In February 2022, Invitae declared that its LiquidPlex Dx and FusionPlex Dx for precision oncology diagnostics are now available in European nations.
  • In July 2021, Immuchrom GmbH, which specialises in oxidative stress, cardiovascular disease, and other gastrointestinal disorders, partnered with Ilex Life Sciences LLC to distribute gastrointestinal biomarker assays throughout the North American continent.

Global Oxidative Stress Assay Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Product, Test Type, Technology, Disease Type, End User, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

  • Instruments
  • Consumables
  • Services

By Test Type:

  • Indirect Assays
  • Antioxidant Capacity Assays
  • Enzyme-Based Assays
  • Reactive Oxygen Species-Based Assays

By Technology:

  • Enzyme-linked Immunosorbent Assay (ELISA)
  • Flow Cytometry
  • Chromatography
  • Microscopy
  • Others

By Disease Type:

  • Cardiovascular disease
  • Respiratory Diseases
  • Cancer
  • Diabetes
  • Others

By End-user:

  • Pharmaceutical and Biotechnology Industries
  • Academic Research institutes
  • Contract Research Organizations
  • Clinical Laboratories
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1.Executive Summary

  • 1.1.Market Snapshot
  • 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1.Oxidative Stress Assay Market, by region, 2020-2030 (USD Billion)
    • 1.2.2.Oxidative Stress Assay Market, by Product, 2020-2030 (USD Billion)
    • 1.2.3.Oxidative Stress Assay Market, by Test Type, 2020-2030 (USD Billion)
    • 1.2.4.Oxidative Stress Assay Market, by Technology, 2020-2030 (USD Billion)
    • 1.2.5.Oxidative Stress Assay Market, by Disease Type, 2020-2030 (USD Billion)
    • 1.2.6.Oxidative Stress Assay Market, by End User, 2020-2030 (USD Billion)
  • 1.3.Key Trends
  • 1.4.Estimation Methodology
  • 1.5.Research Assumption

Chapter 2.Global Oxidative Stress Assay Market Definition and Scope

  • 2.1.Objective of the Study
  • 2.2.Market Definition & Scope
    • 2.2.1.Industry Evolution
    • 2.2.2.Scope of the Study
  • 2.3.Years Considered for the Study
  • 2.4.Currency Conversion Rates

Chapter 3.Global Oxidative Stress Assay Market Dynamics

  • 3.1.Oxidative Stress Assay Market Impact Analysis (2020-2030)
    • 3.1.1.Market Drivers
      • 3.1.1.1.Increasing rRisk of tTargeted dDiseases
      • 3.1.1.2.Rapid Growth in Pharmaceutical & Biotechnology Industry
      • 3.1.1.3.Favourable Government Initiatives
    • 3.1.2.Market Challenges
      • 3.1.2.1.High Cost of Instruments
    • 3.1.3.Market Opportunities
      • 3.1.3.1.Increasing research & development activities by pharmaceutical companies & research institutions
      • 3.1.3.2.Technological Advancements in oxidative stress assays

Chapter 4.Global Oxidative Stress Assay Market: Industry Analysis

  • 4.1.Porter's 5 Force Model
    • 4.1.1.Bargaining Power of Suppliers
    • 4.1.2.Bargaining Power of Buyers
    • 4.1.3.Threat of New Entrants
    • 4.1.4.Threat of Substitutes
    • 4.1.5.Competitive Rivalry
  • 4.2.Porter's 5 Force Impact Analysis
  • 4.3.PEST Analysis
    • 4.3.1.Political
    • 4.3.2.Economical
    • 4.3.3.Social
    • 4.3.4.Technological
    • 4.3.5.Environmental
    • 4.3.6.Legal
  • 4.4.Top investment opportunity
  • 4.5.Top winning strategies
  • 4.6.COVID-19 Impact Analysis
  • 4.7.Disruptive Trends
  • 4.8.Industry Expert Perspective
  • 4.9.Analyst Recommendation & Conclusion

Chapter 5.Global Oxidative Stress Assay Market, by Product

  • 5.1.Market Snapshot
  • 5.2.Global Oxidative Stress Assay Market by Product, Performance - Potential Analysis
  • 5.3.Global Oxidative Stress Assay Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
  • 5.4.Oxidative Stress Assay Market, Sub Segment Analysis
    • 5.4.1. Instruments
    • 5.4.2.Consumables
    • 5.4.3.Services

Chapter 6.Global Oxidative Stress Assay Market, by Test Type

  • 6.1.Market Snapshot
  • 6.2.Global Oxidative Stress Assay Market by Test Type, Performance - Potential Analysis
  • 6.3.Global Oxidative Stress Assay Market Estimates & Forecasts by Test Type 2020-2030 (USD Billion)
  • 6.4.Oxidative Stress Assay Market, Sub Segment Analysis
    • 6.4.1. Indirect Assays
    • 6.4.2.Antioxidant Capacity Assays
    • 6.4.3.Enzyme-Based Assays
    • 6.4.4.Reactive Oxygen Species-Based Assays

Chapter 7.Global Oxidative Stress Assay Market, by Technology

  • 7.1.Market Snapshot
  • 7.2.Global Oxidative Stress Assay Market by Technology, Performance - Potential Analysis
  • 7.3.Global Oxidative Stress Assay Market Estimates & Forecasts by Technology 2020-2030 (USD Billion)
  • 7.4.Oxidative Stress Assay Market, Sub Segment Analysis
    • 7.4.1. Enzyme-linked Immunosorbent Assay (ELISA)
    • 7.4.2.Flow Cytometry
    • 7.4.3.Chromatography
    • 7.4.4.Microscopy
    • 7.4.5.Others

Chapter 8.Global Oxidative Stress Assay Market, by Disease Type

  • 8.1.Market Snapshot
  • 8.2.Global Oxidative Stress Assay Market by Disease Type, Performance - Potential Analysis
  • 8.3.Global Oxidative Stress Assay Market Estimates & Forecasts by Disease Type 2020-2030 (USD Billion)
  • 8.4.Oxidative Stress Assay Market, Sub Segment Analysis
    • 8.4.1. Cardiovascular disease
    • 8.4.2.Respiratory Diseases
    • 8.4.3.Cancer
    • 8.4.4.Diabetes
    • 8.4.5.Others

Chapter 9.Global Oxidative Stress Assay Market, by End User

  • 9.1.Market Snapshot
  • 9.2.Global Oxidative Stress Assay Market by End User, Performance - Potential Analysis
  • 9.3.Global Oxidative Stress Assay Market Estimates & Forecasts by End User 2020-2030 (USD Billion)
  • 9.4.Oxidative Stress Assay Market, Sub Segment Analysis
    • 9.4.1. Pharmaceutical and Biotechnology Industries
    • 9.4.2.Academic Research institutes
    • 9.4.3.Contract Research Organizations
    • 9.4.4.Clinical Laboratories
    • 9.4.5.Others

Chapter 10.Global Oxidative Stress Assay Market, Regional Analysis

  • 10.1.Top Leading Countries
  • 10.2.Top Emerging Countries
  • 10.3.Oxidative Stress Assay Market, Regional Market Snapshot
  • 10.4.North America Oxidative Stress Assay Market
    • 10.4.1.U.S. Oxidative Stress Assay Market
      • 10.4.1.1.Product breakdown estimates & forecasts, 2020-2030
      • 10.4.1.2.Test Type breakdown estimates & forecasts, 2020-2030
      • 10.4.1.3.Technology breakdown estimates & forecasts, 2020-2030
      • 10.4.1.4.Disease Type breakdown estimates & forecasts, 2020-2030
      • 10.4.1.5.End User breakdown estimates & forecasts, 2020-2030
    • 10.4.2.Canada Oxidative Stress Assay Market
  • 10.5.Europe Oxidative Stress Assay Market Snapshot
    • 10.5.1.U.K. Oxidative Stress Assay Market
    • 10.5.2.Germany Oxidative Stress Assay Market
    • 10.5.3.France Oxidative Stress Assay Market
    • 10.5.4.Spain Oxidative Stress Assay Market
    • 10.5.5.Italy Oxidative Stress Assay Market
    • 10.5.6.Rest of Europe Oxidative Stress Assay Market
  • 10.6.Asia-Pacific Oxidative Stress Assay Market Snapshot
    • 10.6.1.China Oxidative Stress Assay Market
    • 10.6.2.India Oxidative Stress Assay Market
    • 10.6.3.Japan Oxidative Stress Assay Market
    • 10.6.4.Australia Oxidative Stress Assay Market
    • 10.6.5.South Korea Oxidative Stress Assay Market
    • 10.6.6.Rest of Asia Pacific Oxidative Stress Assay Market
  • 10.7.Latin America Oxidative Stress Assay Market Snapshot
    • 10.7.1.Brazil Oxidative Stress Assay Market
    • 10.7.2.Mexico Oxidative Stress Assay Market
  • 10.8.Middle East & Africa Oxidative Stress Assay Market
    • 10.8.1.Saudi Arabia Oxidative Stress Assay Market
    • 10.8.2.South Africa Oxidative Stress Assay Market
    • 10.8.3.Rest of Middle East & Africa Oxidative Stress Assay Market

Chapter 11.Competitive Intelligence

  • 11.1.Key Company SWOT Analysis
  • 11.2.Top Market Strategies
  • 11.3.Company Profiles
    • 11.3.1. Abcam Limited
      • 11.3.1.1.Key Information
      • 11.3.1.2.Overview
      • 11.3.1.3.Financial (Subject to Data Availability)
      • 11.3.1.4.Product Summary
      • 11.3.1.5.Recent Developments
    • 11.3.2. AMS Biotechnology (AMSBIO)AMSBIO
    • 11.3.3.Cell Biolabs, Inc.
    • 11.3.4.Enzo Life Sciences, Inc.
    • 11.3.5.Merck KGaA
    • 11.3.6.ImmunoChemistry Technologies
    • 11.3.7.Promega Corporation
    • 11.3.8.QIAGEN N.V.
    • 11.3.9.Thermo Fisher Scientific Inc.
    • 11.3.10.Oxford Biomedical Research

Chapter 12.Research Process

  • 12.1.Research Process
    • 12.1.1.Data Mining
    • 12.1.2.Analysis
    • 12.1.3.Market Estimation
    • 12.1.4.Validation
    • 12.1.5.Publishing
  • 12.2.Research Attributes
  • 12.3.Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦